Raymond James lowered the firm’s price target on Bath & Body Works to $37 from $46 and keeps an Outperform rating on the shares. The firm expects a “tepid” earnings season across the beauty, personal care, and household product group for Q1 as a result of decelerating sales, most notable in the U.S., but also spreading to Europe and Latin America. Demand is slowing as consumers watch their spending on everyday goods, while retailers appear to be prioritizing categories most at risk for tariff-related increases, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body Works price target lowered to $41 from $47 at JPMorgan
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- Bath & Body Works upgraded to Overweight from Neutral at Piper Sandler
- Bath & Body Works price target lowered to $36 from $48 at Citi
- Softlines partially priced in China tariffs, not Vietnam, says Morgan Stanley